TARS

Tarsus Pharmaceuticals, Inc.

16.60 USD
+0.01 (+0.06%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Tarsus Pharmaceuticals, Inc. stock is up 17.56% since 30 days ago. The next earnings date is Mar 11, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 8 November’s closed higher than October. In the last 5 Unusual Options Trades, there were 2 PUTs, 3 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 Nov 14:32 19 Jan, 2024 22.50 PUT 50 200
03 Nov 14:32 19 Jan, 2024 22.50 PUT 50 200
20 Nov 20:36 19 Apr, 2024 17.50 CALL 60 10
20 Nov 20:43 19 Apr, 2024 17.50 CALL 57 10
20 Nov 20:59 19 Apr, 2024 17.50 CALL 70 10

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the. treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction.

  • Goldman Sachs
    Mon Nov 20, 04:41
    hold
    initial
  • HC Wainwright & Co.
    Fri Nov 10, 07:43
    buy
    confirm